ETFs Celltrion, Inc.

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2025-03-14			5-day change	1st Jan Change
186,100.00 ^KRW	+0.81%		+1.14%	-0.75%

04:29am	Nomura Adjusts Celltrion's Price Target to KRW240,000 From KRW230,000, Keeps at Buy	MT
Mar. 14	Celltrion Launches Autoimmune Disease Treatment Biosimilar in US	MT

ETFs positioned on Celltrion, Inc.

Name	Weight	AuM	1st Jan change
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0.53%	17 M€	-1.49%	-
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD	0.06%	8 M€	+4.73%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.05%	9 M€	+7.08%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.05%	33,076 M€	+5.20%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.05%	89 M€	-6.11%	-
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	0.04%	1 M€	-.--%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	53 M€	-3.73%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.02%	467 M€	-2.62%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	61 M€	-2.55%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	619 M€	-4.07%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	139 M€	-1.38%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	28 M€	-1.47%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0.01%	68 M€	-0.27%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	10 M€	-0.34%	-

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,391

Sector

Biotechnology & Medical Research

Calendar

May. 07 - Q1 2025 Earnings Release (Projected)

More about the company